Search results
Moderna director Afeyan sells over $2.3 million in company stock By Investing.com
Investing.com· 3 hours agoModerna , Inc. (NASDAQ:MRNA) director Noubar Afeyan has sold a portion of his holdings in the...
The Moderna News That Has MRNA Stock Price Surging This Week: 3 Key Catalysts
InvestorPlace· 1 day agoModerna (NASDAQ:MRNA) stock is up more than 20% in just the past five trading sessions as investors foresee strong growth opportunities for the biotechnology firm. Indeed, ...
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
Zacks via Yahoo Finance· 2 weeks agoModerna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...
Why Vaccine Stocks Rallied This Week
The Motley Fool via AOL· 14 hours agoShares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and...
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Benzinga· 1 week agoModerna Inc MRNA has reportedly achieved a significant victory at the European Patent Office (EPO)...
Heard on the Street: Moderna Got a Boost From Bird Flu, but Don’t Count Your Chicks
The Wall Street Journal· 1 day agoModerna, BioNTech, CureVac and Novavax have added billions of dollars in combined market...
Moderna and this solar name are among the most overbought stocks after a record-setting week
CNBC· 9 hours agoIt may be time for investors to trim positions in overbought names after the stock market reached...
Moderna’s long Covid plan
Politico· 1 day agoModerna is eyeing a new target: long Covid. The pharmaceutical company that became a household name when it developed a Covid-19 vaccine now wants to...
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
Motley Fool via Yahoo Finance· 2 weeks agoModerna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every...
Is This a Setback for Moderna?
The Motley Fool via AOL· 2 weeks agoInvestors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it...
